Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Open-Label Study of Cell Culture-Derived H7N9 Influenza Vaccine (IDCDC-RG56N) in Healthy Adults
jRCTs031200112Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of cell culture-derived H7N9 influenza vaccine in avian influenza A H7N9 (A(H7N9)), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Antibody titer response to H7N9 vaccine. Started Sep 2020; status: completed.
02
Drugs
cell culture-derived H7N9 influenza vaccine
03
Conditions
avian influenza A H7N9 (A(H7N9))
Beyond the preview
Go deeper on jRCTs031200112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200112.